SensiScreen®
11Pages

The sensible choice for somatic mutation detection SensiScreen® assays are real-time PCR-based reactions for somatic mutation detection in cancer patients. SensiScreen® combines high sensitivity with multiplexing capabilities, ease-of-use and is designed to work on standard real-time PCR equipment. Sensitive detection of somatic mutations by SensiScreen® is achieved with PentaBase’s novel and selective INA® technologies including the use of BaseBlockers™ that suppress false positive signals from wild type templates. Key features • High sensitivity - down to one copy detection • Simplex and multiplex configurations • Mutation detection in solid and liquid biopsies • Open platform designs From sample to answer in less than three hours SensiScreen® assays are supplied as either “Ready to use” or as “Dispense Ready” mixes. Ready to use assays are pre-dispensed in PCR strips and require only addition of genomic DNA (gDNA) for somatic mutation testing. Dispense-ready mixes include oligonucleotides and master mix in separate tubes ready to be dispensed and added gDNA. The technology is applicable on standard real-time equipment using standard procedures and results can be ready in less than three hours from receiving a sample (including automated DNA extraction). Streamline your workflow with SensiScreen® multiplex assays Less than 2 minutes hands-on time per sample gDNA extraction More information at www.pentabase.com Add purified gDNA to SensiScreen® Ready to use or Dispense rea

Ultra-sensitive detection of somatic mutations by SensiScreen® is possible with PentaBase’s novel and selective technologies, comprising: 1. HydrolEasy™ dual-labelled probes with significantly improved signal-to-noise ratio and higher specificity compared to conventional hydrolysis probes. 2. Suprimer™ DNA primers modified with pentabases for specific and sensitive amplification. 3. BaseBlockers™ suppressing false positive and negavtive signals from wild type templates and ensuring high specificity and robustness of the assays. SensiScreen® assay design Principle of BaseBlockers™....

Sensi screen® Liquid Made by PentaBase Early detection and monitoring with ultra high sensitivity SensiScreen® Liquid assays are designed for early detection and monitoring of somatic mutations in liquid biopsies using standard equipment. With SensiScreen® Liquid, it is possible to monitor changing levels of mutant DNA and newly developed mutations in circulating cell-free DNA (ccfDNA) shed into the blood or other liquid samples. In this way, SensiScreen® Liquid can support the selection of the most appropriate personalized treatment in a timely manner. SensiScreen® Liquid assays are able...

Colorectal Cancer Disease Progression Monitoring SensiScreen® Liquid BRAF V600E 160 120 80 40 Targeted Therapy A colorectal cancer case study using SensiScreen® BRAF V600E Liquid for disease monitoring. Approx. 200 µl of plasma were used. Choose SensiScreen® Liquid for fast and sensitive cancer monitoring using liquid biopsies For any inquiries, please write to info@pentabase.com or go to www.pentabase.com. More information at www.pentabase.co

FFPE Detection in solid biopsies SensiScreen® FFPE assays are designed for detection of somatic mutations from genomic DNA in solid biopsies like fresh, frozen, FFPE tissue, or other samples with high amounts of DNA. SensiScreen® FFPE assays are able to robustly detect 0.25-1 % mutation in a 50 ng wild type background. • Analysis of primary tumors and metastases • Multiplex assays for screening of cancer mutation hotspots • Simplex assays for genotyping and has confirmation • SensiScreen FFPE assays are applicable to fresh, frozen or FFPE biopsies SensiScreen® KRAS G12V sensitivity...

Colorectal Cancer Panels Colorectal cancer (CRC) is one of the leading causes of cancer related mortality. Progression of CRC is associated with accumulation of mutations in the EGFR signalling pathway(s) involving genes like KRAS, NRAS, BRAF and PIK3CA. Treatment efficacy of available therapies (like the selection of EGFR antagonizing antibodies) rely on tumor mutation profiling, stratification and monitoring. PentaBase SensiScreen® CRC panels have been developed to support initial selection of adequate treatment regimen and subsequent monitoring of treatment efficacy and resistance...

Colorectal Cancer Panels PentaBase offers SensiScreen® somatic mutation panels for tumor development monitoring and stratification of colorectal cancer patients with unprecedented sensitivites SensiScreen® Liquid monitoring SensiScreen® FFPE tumor stratification • Detects down to 1 copy of mutated DNA • Analysis of primary tumors and metastases • Multiplex assays for hotspot CRC mutations • Analysis of liquid biopsies • Early detection and monitoring of cancer DNA • From biopsy to result in < 3 hours • Simplex assays for genotyping and NGS confirmation • SensiScreen® FFPE assays are...

Lung Cancer Panels Non-small-cell lung cancer (NSCLC) is the most widespread type of lung cancer and accounts for the highest mortality rates among cancers. NSCLC is relatively insensitive to chemotherapeutics and radiation therapy, but recently a number of new drugs have been developed. PentaBase’s SensiScreen® Lung cancer panels have been developed to support initial selection of adequate treatment regimen and subsequent monitoring of treatment efficacy and resistance development SensiScreen®Liquid and FFPE lung cancer panels EGFR Exon 18+19+20+21 Multiplex BRAF V600D/E/K/R Multiplex and...

Lung Cancer Panels PentaBase offers SensiScreen® somatic mutation panels for unprecedented sensitive tumor development monitoring and stratification of lung cancer patients SensiScreen® Liquid SensiScreen® FFPE tumor stratification Key features • Analysis of primary tumors and metastases • Detects down to 1 copy of mutated DNA • Multiplex assays for hotspot lung cancer mutations • Analysis of liquid biopsies • Early detection and monitoring of tumor DNA • From biopsy to result in < 3 hours • Simplex assays for genotyping and NGS confirmation • SensiScreen® FFPE assays are applicable to...